 |
The Commitment to Care program is designed to ensure that eligible individuals, including Medicare beneficiaries who meet our criteria, have access to Schering-Plough's cancer and hepatitis drugs. These medicines include:
| • |
PEGINTRON (peginterferon
alfa-2b) Powder for Injection; |
| • |
REBETOL (ribavirin,
USP) Capsules; |
| • |
INTRON A (Interferon
alfa-2b, recombinant) for Injection; |
| • |
NOXAFIL (posaconazole) Oral Suspension |
| • |
TEMODAR (temozolomide)
Capsules; |
| • |
TICE BCG, BCG LIVE (for intravesical use) |
The Commitment to Care program's reimbursement specialists provide eligible patients with all aspects of reimbursement assistance at no cost, including:
- insurance verification,
- pre-authorization or pre-certification,
- assistance appealing insurance denials, and
- referrals to state and local assistance programs.
In addition, the program distributed pharmaceutical products free of charge to more than 4,700 needy patients in 2007.
Unlike many other reimbursement programs, Commitment to Care is telephone based, offers patients easy access to a reimbursement assistance specialist with rapid follow up, and eliminates extensive paperwork.
Click here for the Commitment to Care
Application.
To find out more about the Commitment to Care program, call toll
free: 1-800-521-7157.
|
